Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China National Accord Medicines (SZSE:200028) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
China National Accord Medicines Cash Conversion Cycle Related Terms
China National Accord Medicines Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China National Accord Medicines Cash Conversion Cycle Chart
SZSE:200028 vs MCK, COR, CAH: Cash Conversion Cycle Comparison
For the Medical Distribution subindustry, China National Accord Medicines's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China National Accord Medicines Cash Conversion Cycle vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China National Accord Medicines's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where China National Accord Medicines's Cash Conversion Cycle falls into.
China National Accord Medicines Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China National Accord Medicines (SZSE:200028) has a Cash Conversion Cycle of 48.39 as of Jun. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on China National Accord Medicines and its competitors.
Is China National Accord Medicines' Cash Conversion Cycle too high?
China National Accord Medicines' current Cash Conversion Cycle is 48.39. The Medical Distribution industry median Cash Conversion Cycle is 57.67. China National Accord Medicines' value of 48.39 is 16.1% below this industry median. Overall, China National Accord Medicines has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Accord Medicines' Cash Conversion Cycle compare to MCK and COR?
China National Accord Medicines' Cash Conversion Cycle of 48.39 can be compared against companies in the Medical Distribution industry. The industry median Cash Conversion Cycle is 57.67. China National Accord Medicines' value of 48.39 is 16.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Distribution company?
The median Cash Conversion Cycle among Medical Distribution companies is 57.67, based on 123 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China National Accord Medicines's current Cash Conversion Cycle of 48.39 is 16.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on China National Accord Medicines and its competitors. For the Medical Distribution industry, the median Cash Conversion Cycle is 57.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China National Accord Medicines's current Cash Conversion Cycle is 48.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Accord Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Accord Medicines (SZSE:200028) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$13.65, compared to a current price of HK$12.01 — trading 12% below its estimated fair value. The current Cash Conversion Cycle is 48.39 and 16.1% below the Medical Distribution industry median of 57.67. China National Accord Medicines' overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For China National Accord Medicines (SZSE:200028), the current Cash Conversion Cycle is 48.39 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China National Accord Medicines (SZSE:200028) Overvalued in 2026?
Based on GuruFocus' analysis, China National Accord Medicines stock appears to be undervalued.
The current stock price of HK$12.01 is trading 12% below its estimated GF Value™ of HK$13.65.
GuruFocus considers China National Accord Medicines to be Modestly Undervalued.
Key valuation signals for SZSE:200028:
Cash Conversion Cycle: 48.39
GF Value™: HK$13.65 vs. price of HK$12.01 (12% below fair value)
Industry Position: 16.1% below the Medical Distribution median
No single metric tells the full story. See the SZSE:200028 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.
82GF Score
Get the complete analysis for SZSE:200028
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:200028 has been successfully added to your 
